Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-210-3p mimic
- Development stage
- Unknown
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-210-3p mimic is a synthetic double-stranded RNA oligonucleotide designed to mimic the activity of endogenous microRNA-210-3p (miR-210-3p). It is widely utilized as a research-use-only (RUO) laboratory tool to investigate the physiological and pathological roles of miR-210-3p, particularly in cellular responses to hypoxia, angiogenesis, and ischemia-reperfusion injury. In experimental models, transfection of cells (such as glomerular endothelial cells or renal tubular cells) with miR-210-3p mimic downregulates key target genes, including hypoxia-inducible factor 1-alpha (HIF1A), transferrin receptor 1 (TFRC), and transforming growth factor beta receptor 1 (TGFBR1). This modulation can enhance glycolytic capacity and provide cytoprotective effects under hypoxic conditions, making it a subject of interest for research into organ preservation and acute kidney injury.
- Other names
- hsa-miR-210-3p mimichsa-miR210-3p mimichsa-miR 210-3p mimicmicroRNA-210-3p mimicmicroRNA210-3p mimicmicroRNA 210-3p mimicmmu-miR-210-3p mimicmmu-miR210-3p mimicmmu-miR 210-3p mimic
02
Targets
ID4 (DNA-binding protein inhibitor 4)HIF1A (Hypoxia-inducible factor 1-alpha)SOCS1 (Suppressor of cytokine signaling 1)TGFBR1E2F3 (Transcription factor E2F3)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on miR-210-3p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-210-3p mimic.